At the current research stage, low-dose IL-2 combined with PD-1 agonist has been confirmed to be effective in treating SLE in pre-clinical trials, and in-depth research is required for the selection of drugs in clinical treatment. This evidence concerns the gene PDCD1 and systemic lupus erythematosus.